Corner Therapeutics to hyperactivate ‘the brains of the immune system’ with $54M launch

Cor­ner Ther­a­peu­tics’ $54 mil­lion Se­ries A will be used to bring new im­munother­a­pies for can­cer and in­fec­tious dis­eases in­to the clin­ic, the com­pa­ny said Thurs­day.

The start­up is led by Steve Altschuler, who co-found­ed Spark Ther­a­peu­tics and was pre­vi­ous­ly CEO of the Chil­dren’s Hos­pi­tal of Philadel­phia. Altschuler serves as the man­ag­ing di­rec­tor of health­care ven­tures at Ziff Cap­i­tal Part­ners, which led Cor­ner’s Se­ries A raise. Cock­rell In­ter­ests, Ta­nis Ven­tures and San­dia Hold­ings al­so con­tributed to the raise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.